MLYS
Insider sale, meet the fine print
Mineralys Therapeutics got a little insider-trading footnote this week: Chief Medical Officer David Malcom Rodman sold 20,406 shares of common stock for roughly $548,672 across April 13 and April 15, 2026. The stock sold in a range of $26.5391 to $27.66 a share.
The important asterisk
This wasn’t some dramatic “running for the exits” moment. The trades were made under a pre-arranged Rule 10b5-1 plan adopted back on October 6, 2025 — basically the corporate version of setting your coffee timer before you even wake up. That makes the sale much less alarming than a surprise dump.
Rodman also exercised options to acquire 14,058 shares on April 13 at prices ranging from $1.08 to $14.25, which is a nice reminder that insider transactions can be more accounting puzzle than headline grenade. In other words: not all selling is bearish, especially when options are involved.
Why investors care
The market’s already had a big run here — the shares are now around $30.42 and up sharply over the past year — so any insider activity gets extra eyeballs. On its own, this looks more like routine portfolio housekeeping than a thesis-breaking event.
Big picture: if you own MLYS, this is less “uh-oh” and more “keep scrolling, but maybe keep an eye on the tape.”